Vifor Patent-Cliff Exposure & CMS Drug Spending Portfolio

Vifor (US): 1 reconciled FDA prescription therapies (100.0% 2025 to 2030 cliff risk), $192.3M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure100.0%
Primary Portfolio LOE Date2033-01-01
2024 CMS Total Public Spend$192.3M
2024 Medicare Part D Spend$175.1M
2024 Medicaid Spend$17.2M
California HCAI SB 17 Filings0 statutory filings in 2023 to 2026 panel